Ho Maria Y, Mackey John R
Division of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada.
Cancer Manag Res. 2014 May 27;6:253-9. doi: 10.2147/CMAR.S40601. eCollection 2014.
The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic setting. Although well tolerated by the majority of patients, docetaxel toxicity may limit the dose which can be administered. Adverse events include infusion reactions, febrile neutropenia, fatigue, fluid retention, pneumonitis, cutaneous and nail toxicity, epiphora and lacrimal duct stenosis, gastrointestinal complications, and neuropathies. In this review, we explore these complications and how they can be effectively managed to improve patient quality of life during and following docetaxel therapy.
紫杉烷类化疗药物多西他赛已被用于辅助、新辅助和转移性乳腺癌的治疗。尽管大多数患者对多西他赛耐受性良好，但多西他赛的毒性可能会限制给药剂量。不良事件包括输注反应、发热性中性粒细胞减少、疲劳、液体潴留、肺炎、皮肤和指甲毒性、流泪和泪道狭窄、胃肠道并发症以及神经病变。在本综述中，我们探讨了这些并发症以及如何有效管理它们，以改善多西他赛治疗期间及之后患者的生活质量。
